At Gordian we have scaled in vivo discovery of genetic therapeutics, toward curing age-related diseases. Using our proprietary platform, we measure in vivo efficacy of hundreds of gene therapies with different gene targets simultaneously, in individual animal models of disease.

We have screened over 1000 gene therapies across three indications to date: Heart Failure, Metabolic Associated Steatohepatitis (MASH), and Osteoarthritis, building the largest in vivo gene perturbation dataset on the planet. Top therapies have been validated in preclinical POC experiments, and will advance toward IND enabling studies and clinical development both internally and through pharma partnerships. For these collaborations, we solve target risk where a partner wants to leverage established delivery technology (e.g. AAV, LNP, nucleic acid, etc) for a complex indication.

Contact Gordian Biotechnology
Visit Website